Centessa Announces Pricing of Initial Public Offering

May 28, 2021
CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–May 27, 2021– Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company
employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today the
pricing of its initial public offering of 16,500,000 American Depositary Shares (“ADSs”), each representing one ordinary share at a public offering price
of $20.00 per ADS. All of the ADSs are being offered by Centessa. The gross proceeds to Centessa from the offering, before deducting underwriting
discounts, commissions and other estimated offering expenses, are expected to be approximately $330.0 million. In addition, the underwriters have
been granted a 30-day option to purchase up to an additional 2,475,000 ADSs at the initial public offering price, less underwriting discounts and
commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “CNTA” on May 28, 2021. The
offering is expected to close on June 2, 2021, subject to the satisfaction of customary closing conditions.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH